Qiagen N.V. (LON:0RLT)
41.03
-0.10 (-0.25%)
At close: Jun 27, 2025
Qiagen Revenue
Qiagen had revenue of $483.46M USD in the quarter ending March 31, 2025, with 5.37% growth. This brings the company's revenue in the last twelve months to $2.00B, up 3.31% year-over-year. In the year 2024, Qiagen had annual revenue of $1.98B with 0.66% growth.
Revenue (ttm)
$2.00B
Revenue Growth
+3.31%
P/S Ratio
4.94
Revenue / Employee
$371.18K
Employees
5,396
Market Cap
7.67B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.98B | 12.90M | 0.66% |
Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
Dec 31, 2020 | 1.87B | 343.92M | 22.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
Shell | 217.54B |
HSBC Holdings | 44.89B |
Unilever | 50.25B |
Rolls-Royce Holdings | 18.91B |
British American Tobacco p.l.c. | 25.87B |
Rio Tinto Group | 42.86B |
RELX PLC | 9.43B |
Qiagen News
- 7 days ago - QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board - Business Wire
- 15 days ago - Qiagen and Gencurix Enter Clinical Diagnostics Partnership - Market Watch
- 15 days ago - Qiagen and Gencurix partner for oncology tests - Seeking Alpha
- 15 days ago - QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership - Business Wire
- 17 days ago - Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Benzinga
- 19 days ago - QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Business Wire
- 27 days ago - Tracer Biotechnologies and QIAGEN to advance blood-based MRD testing for solid tumors - Seeking Alpha
- 4 weeks ago - Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors - Business Wire